Lysosomal Storage Diseases Market : The end-user segment of hospitals is expected to account for 66.9% of sales by the end of 2016

Persistence Market Research provides key insights on the global Lysosomal Storage Disease Therapeutics Market in a new report titled, “Lysosomal Storage Disease Therapeutics Market: Global Industry Analysis and Forecast, 2016-2026”. In terms of revenue, the global Lysosomal Storage Disease Therapeutics Market is anticipated to register a healthy CAGR of 10.0% during the forecast period and is valued at US$14.36 billion by 2026. In the report, Persistence Market Research analyzes the key factors and trends affecting the growth and performance of the global Lysosomal Storage Disease Therapeutics Market during the forecast period.

Request a Free Sample Report on Lysosomal Storage Diseases Market”@ https://www.persistencemarketresearch.com/samples/3145

Drivers and trends affecting the market

Increasing diagnosis rate due to increasing awareness and financial incentives for orphan drug development to cover R&D costs is the main factor driving the growth of the global lysosomal storage disease therapeutics market. Also, an increasing focus by major biopharmaceutical companies on research and development of drugs to treat rare diseases is expected to boost the global lysosomal storage disease therapeutics market during the forecast period. Furthermore, the number of treatment options currently in the pipeline are expected to further fuel the revenue growth of the global Lysosomal Storage Disease Therapeutics market during the forecast period.

However, disease heterogeneity leading to underdiagnosis of lysosomal storage diseases, lack of treatment options and high cost of treatment are factors that are likely to hamper the growth of the global lysosomal storage disease therapeutics market during the forecast period.

companies

• Shire PLC
• Pfizer, Inc.
• Sanofi
• BioMarin Pharmaceutical Inc.
• Actelion Ltd.
• Birds of prey…